Canine Oral Chewable Tablets Market are the oral dosage form of medication with additives used to treat various types of canine diseases such as arthritis, canine congestive heart failure, tick and fleas infections, and among others. Various additives and flavouring agents are used in the formulation of canine oral chewable tablets for masking the unpleasant taste and odour of the drugs. The canine oral chewable tablets will dissolve in 2-5 minutes and the pharmacological action takes place immediately. The global canine oral chewable tablets market is in the developing stage as several local and international players are actively engaged in the manufacturing of canine oral chewable tablets for the treatment of chronic canine diseases. Acquisitions and mergers, collaborations, joint ventures, and product launches, are some key strategies followed by the manufacturers for increasing their share in the global market. For instance, in December 2015, Boehringer Ingelheim acquired Merial (Sanofi animal health) for strengthening its product portfolio. In addition, in May 2014, Merck Animal Health received the FDA approval for its drug Bravecto (fluralaner) used in the treatment of fleas and ticks infections. Moreover, in December 2014, Putney, Inc. launched the Carprofen canine oral chewable tablets for the treatment of pain and inflammation.